Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team, Medical Monitors

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Current therapeutic development in amyotrophic lateral sclerosis (ALS) relies on individual randomized clinical trials to test a specific investigational product in a single patient population. This approach has intrinsic limitations, including cost, time, and lack of flexibility. Adaptive platform trials represent a novel approach to investigate several interventions for a single disease in a continuous manner. Already in use in oncology, this approach is now being employed more often in neurology. Here, we describe a newly launched platform trial for ALS. The Healey ALS Platform Trial is testing multiple investigational products concurrently in people with ALS, with the goal of rapidly identifying novel treatments, biomarkers, and trial endpoints. ANN NEUROL 2022;91:165–175.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalAnnals of Neurology
Issue number2
StatePublished - Feb 1 2022

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development'. Together they form a unique fingerprint.

Cite this